Investing.com - Jazz Pharma (NASDAQ: JAZZ) reported second quarter EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32M versus the consensus estimate of $941.99M.
Jazz Pharma's stock price closed at $133.00. It is down -2.00% in the last 3 months and down -15.52% in the last 12 months.
Jazz Pharma saw 3 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Jazz Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Jazz Pharma's Financial Health score is "great performance".
Check out Jazz Pharma's recent earnings performance, and Jazz Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar